{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:06:27Z","timestamp":1768925187152,"version":"3.49.0"},"reference-count":100,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Numerous epidemiological studies have shown that hypertriglyceridemia is a significant risk factor for cardiovascular diseases (CVD). However, large clinical studies on triglyceride\u2010lowering therapy have yielded inconsistent results. In the current review, we reassess the importance of triglyceride\u2010lowering therapy in preventing CVD based on previous literature and the recently published findings of the PROMINENT trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This narrative review is based on literature and public documents published up to November 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Meta\u2010analyses of trials on peroxisome proliferator\u2010activated receptor \u03b1 agonists and triglyceride\u2010lowering therapy, including the PROMINENT trial, have indicated that triglyceride\u2010lowering therapy can reduce CVD events. Mendelian randomization studies have also indicated that triglyceride is indeed a true risk factor for coronary artery disease, leaving no doubt about its relationship to CVD. Meanwhile, the negative results from the PROMINENT trial were likely due to the insufficient triglyceride\u2010lowering effect, slight increases in low\u2010density lipoprotein cholesterol and apolipoprotein B, and the inclusion of mostly high\u2010intensity statin users as target patients. It is unlikely that adverse events counteracted the effectiveness of pemafibrate on outcomes. Additionally, pemafibrate has shown positive effects on non\u2010alcoholic fatty liver disease and peripheral artery disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although the PROMINENT trial did not demonstrate the significance of pemafibrate as a triglyceride\u2010lowering therapy in a specific population, it does not necessarily negate the potential benefits of treating hypertriglyceridemia in reducing CVD events. It is necessary to explore appropriate populations that could benefit from this therapy, utilize data from the PROMINENT trial and other databases, and validate findings in real\u2010world settings.<\/jats:p><\/jats:sec>","DOI":"10.1111\/eci.14227","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T16:49:33Z","timestamp":1714063773000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Managing hypertriglyceridemia for cardiovascular disease prevention: Lessons from the PROMINENT trial"],"prefix":"10.1111","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6645-4185","authenticated-orcid":false,"given":"Shizuya","family":"Yamashita","sequence":"first","affiliation":[{"name":"Rinku General Medical Center  Izumisano Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Hirano","sequence":"additional","affiliation":[{"name":"Diabetes Center, Ebina General Hospital  Ebina Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Shimano","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Institute of Medicine University of Tsukuba  Tsukuba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Teikyo University School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics Tokyo Medical and Dental University  Tokyo Japan"},{"name":"Department of Life Science and Bioethics, Graduate School of Medicine Tokyo Medical and Dental University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8840-5245","authenticated-orcid":false,"given":"Hiroshi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Section of Internal Medicine of Metabolism and Nutrition The Jikei University Graduate School of Medicine  Tokyo Japan"},{"name":"Department of General Medicine The Jikei University Kashiwa Hospital  Chiba Japan"},{"name":"Department of Laboratory Medicine The Jikei University Kashiwa Hospital  Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"issue":"25","key":"e_1_2_12_2_1","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy SM","year":"2019","journal-title":"Circulation"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.04.059"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13537"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab551"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2011.02.019"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.637793"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.04.008"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.03.544"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61177-6"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2015.241752"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu208"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3525-8"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/2047487318796989"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-023-00634-0"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.GL2017"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.117187"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107579"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300955"},{"issue":"74","key":"e_1_2_12_20_1","first-page":"22612","article-title":"AbbVie Inc. et\u00a0al. Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended\u2010 release tablets and fenofibric acid delayed\u2010release capsules","volume":"81","author":"Federal Register","year":"2016","journal-title":"Food and Drug Administration"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60527-3"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812792"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22258"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.04.027"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198711123172001"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908053410604"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.1.21"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001282"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60656-3"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000862"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.04.020"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1106688"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20200305"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.48918"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225537"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13050626"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210645"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.02.029"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.44412"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2018.06.010"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.03.032"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030706"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1589"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.10.006"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12845"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1288"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16596"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.041998"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14013"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.04.009"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.63358"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100624"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.63940"},{"key":"e_1_2_12_55_1","unstructured":"ArakiE YamashitaS AraiH et\u00a0al.Efficacy and safety of pemafibrate a selective PPAR\u03b1 modulator (SPPARM\u03b1) in patients with pathological conditions attributed to insulin resistance: a pooled analysis from 6 placebo\u2010controlled Phase 2 and 3 trials in Japan. Orally presented at: the 53rd Annual Scientific Meeting of the Japan Atherosclerosis Society; Oct 23\u201324 2021; Kyoto Japan."},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0800370"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2019.12.006"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9"},{"issue":"21","key":"e_1_2_12_60_1","article-title":"Abstract 10453: Impact of diabetes duration on atheroma progression in diabetic patients with coronary artery disease: Insights from serial intravascular ultrasound","volume":"124","author":"Yu K","year":"2018","journal-title":"Circulation"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwad331"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12216915"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14076"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2018.09.006"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2216470"},{"issue":"10","key":"e_1_2_12_67_1","first-page":"955","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"388","author":"Oliva\u2010Damaso N","year":"2023","journal-title":"N Engl J Med"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1159\/000064083"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp120131"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.129197"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.61101"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.31662\/jmaj.2021-0212"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.63659"},{"key":"e_1_2_12_74_1","first-page":"453","article-title":"A long\u2010term, prospective post\u2010marketing surveillance of pemafibrate\u2010interim report at 3 months","volume":"51","author":"Ishibashi S","year":"2023","journal-title":"Pharmacol Ther"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2012-0078"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318258"},{"issue":"11","key":"e_1_2_12_77_1","first-page":"785","article-title":"Thrombosis and platelets: an update","volume":"38","author":"Koupenova M","year":"2017","journal-title":"Eur Heart J"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60698-X"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.315828"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab705"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18052384"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1177\/147323000903700204"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235362"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1073025"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16222"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep42477"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64902-8"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325724"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000000000000153"},{"key":"e_1_2_12_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2009.151"},{"key":"e_1_2_12_91_1","doi-asserted-by":"publisher","DOI":"10.1159\/000182614"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10228"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2018.04.474"},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01477001"},{"key":"e_1_2_12_95_1","volume-title":"Parmodia Film\u2010Coated Tablets 0.1 mg","year":"2022"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2018.04.475"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01291-w"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1235"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.726"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad248"},{"issue":"25","key":"e_1_2_12_101_1","first-page":"e282","article-title":"23102: Pemafibrate reduces incidence of lower extremity ischemic ulcer and gangrene: Evidence from PROMINENT","volume":"148","author":"Marinho L","year":"2023","journal-title":"Circulation"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/eci.14227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T12:27:11Z","timestamp":1738326431000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/eci.14227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":100,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/eci.14227"],"URL":"https:\/\/doi.org\/10.1111\/eci.14227","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"2023-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14227"}}